These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 24955220)

  • 1. The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression.
    Traish AM; Mulgaonkar A; Giordano N
    Korean J Urol; 2014 Jun; 55(6):367-79. PubMed ID: 24955220
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Negative Impact of Testosterone Deficiency and 5α-Reductase Inhibitors Therapy on Metabolic and Sexual Function in Men.
    Traish AM
    Adv Exp Med Biol; 2017; 1043():473-526. PubMed ID: 29224108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New steroidal 17β-carboxy derivatives present anti-5α-reductase activity and anti-proliferative effects in a human androgen-responsive prostate cancer cell line.
    Amaral C; Varela C; Correia-da-Silva G; Tavares da Silva E; Carvalho RA; Costa SC; Cunha SC; Fernandes JO; Teixeira N; Roleira FM
    Biochimie; 2013 Nov; 95(11):2097-106. PubMed ID: 23933094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    World J Urol; 2002 Apr; 19(6):413-25. PubMed ID: 12022710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
    Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
    J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
    Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
    Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients.
    Traish AM; Hassani J; Guay AT; Zitzmann M; Hansen ML
    J Sex Med; 2011 Mar; 8(3):872-84. PubMed ID: 21176115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
    Tarter TH; Vaughan ED
    Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia.
    Shin YS; Karna KK; Choi BR; Park JK
    World J Mens Health; 2019 May; 37(2):157-165. PubMed ID: 30209896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors.
    Wu Y; Godoy A; Azzouni F; Wilton JH; Ip C; Mohler JL
    Prostate; 2013 Sep; 73(13):1470-82. PubMed ID: 23813697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride.
    Kaplan SA; Chung DE; Lee RK; Scofield S; Te AE
    Int J Clin Pract; 2012 Nov; 66(11):1052-5. PubMed ID: 23067029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health Risks Associated with Long-Term Finasteride and Dutasteride Use: It's Time to Sound the Alarm.
    Traish AM
    World J Mens Health; 2020 Jul; 38(3):323-337. PubMed ID: 32202088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive management of lower urinary tract symptoms and sexual dysfunction associated with benign prostatic hyperplasia in the primary care setting.
    Kuritzky L
    Compr Ther; 2005; 31(3):194-208. PubMed ID: 16110128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride, not tamsulosin, increases severity of erectile dysfunction and decreases testosterone levels in men with benign prostatic hyperplasia.
    Traish AM; Haider KS; Doros G; Haider A
    Horm Mol Biol Clin Investig; 2015 Sep; 23(3):85-96. PubMed ID: 26053014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An overview on 5alpha-reductase inhibitors.
    Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
    Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
    Lowe FC
    BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer.
    Tindall DJ; Rittmaster RS
    J Urol; 2008 Apr; 179(4):1235-42. PubMed ID: 18280514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.
    Clark RV; Hermann DJ; Cunningham GR; Wilson TH; Morrill BB; Hobbs S
    J Clin Endocrinol Metab; 2004 May; 89(5):2179-84. PubMed ID: 15126539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.